Company research
bioAffinity Technologies, Inc.
CIK 1712762Updated Sep 26, 2026
Name history
bioAffinity Technologies, Inc. · through Sep 22, 2026
BIAF price & chart
Loading TradingView…
NASDAQ:BIAF on TradingView ↗About the company
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
In the news
Big Pharma Setbacks Create a New Wave of Rebound Plays ↗
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules ↗
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering ↗
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
424B3 filing
Show 5 more recent filings
EFFECT filing
Other Events
Items 8.01, 9.01
S-3/A filing
8-K filing
S-3 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Property, Plant and Equipment, NetUSD | 265,593Source | 375,385Source | 458,633Source | 214,438Source |
| GoodwillUSD | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 716,806Source | 775,139Source | 833,472Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,449,782Source | 1,105,291Source | 2,821,570Source | 11,413,759Source |
| Inventory, NetUSD | 53,548Source | 27,608Source | 18,484Source | 5,540Source |
| Assets, CurrentUSD | 7,565,208Source | 2,695,098Source | 3,972,745Source | 11,961,687Source |
| Prepaid Expense and Other Assets, CurrentUSD | 519,916Source | 422,995Source | 321,017Source | 531,899Source |
| Operating Lease, Right-of-Use AssetUSD | 334,289Source | 463,011Source | 370,312Source | — |
| Other Assets, NoncurrentUSD | 12,815Source | 19,676Source | 16,060Source | 6,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,683,116Source | 3,911,631Source | 3,366,297Source | 1,138,682Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 1Source | — | — | — |
| Common Stock, Value, IssuedUSD | 31,461Source | 106,593Source | 65,762Source | 58,669Source |
| Additional Paid in CapitalUSD | 75,800,258Source | 56,139,753Source | 49,393,972Source | 47,652,242Source |
| Retained Earnings (Accumulated Deficit)USD | -68,554,064Source | -53,644,310Source | -44,604,479Source | -36,667,468Source |
| Stockholders' Equity Attributable to ParentUSD | 7,277,656Source | 2,602,036Source | 4,855,255Source | 11,043,443Source |
| Liabilities and EquityUSD | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,906,166Source | 3,104,905Source | 2,247,829Source | 1,138,682Source |
| Operating Lease, Liability, CurrentUSD | 139,220Source | 127,498Source | 94,708Source | — |
| Accounts Payable, CurrentUSD | 761,901Source | 987,311Source | 604,789Source | 345,042Source |
| Operating Lease, Liability, NoncurrentUSD | 202,878Source | 342,098Source | 283,001Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,717,989Source | 1,398,722Source | 1,149,811Source | 541,894Source |
| Deferred Revenue, CurrentUSD | 42,405Source | 24,404Source | 33,058Source | — |
| Deferred Tax Liabilities, NetUSD | 184,998Source | 311,678Source | 137,014Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 8,600,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 671,474Source | 989,681Source | 748,823Source | 248,592Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 25,940Source | 9,124Source | 12,944Source | 5,540Source |
| Increase (Decrease) in Accounts PayableUSD | -225,410Source | 382,521Source | -14,501Source | 114,635Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,328,842Source | -7,264,795Source | -6,037,806Source | -4,070,845Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 2,186,497Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -60,568Source | -79,083Source | -2,209,399Source | -219,987Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 60,568Source | 79,083Source | 22,902Source | 219,987Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,733,901Source | 5,627,599Source | -344,984Source | 14,343,953Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 5,344,491Source | -1,716,279Source | -8,592,189Source | 10,053,121Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 44,042Source | 17,610Source | 37,125Source | 30,637Source |
| Income Taxes Paid, NetUSD | 23,385Source | 11,650Source | 20,993Source | 2,459Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 2,055,627Source |
| Share-based Payment Arrangement, ExpenseUSD | 671,474Source | 989,681Source | 748,823Source | 248,592,000Source |
| Amortization of Intangible AssetsUSD | 58,334Source | 58,333Source | 16,528Source | — |
| DepreciationUSD | 170,359Source | 162,332Source | 233,064Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 212,258Source |
| GoodwillUSD | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Income Tax Expense (Benefit)USD | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| InterestExpenseNonoperatingUSD | 44,372Source | 92,475Source | — | — |
| Investment Income, InterestUSD | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Net Income (Loss) Attributable to ParentUSD | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Nonoperating Income (Expense)USD | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Proceeds from Stock Options ExercisedUSD | — | 74,899Source | — | 74,900Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,161,959Source | 9,362,022Source | — | 4,803Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 9,913,729Source | 9,943,473Source | 6,790,654Source | 2,727,071Source |
| Operating Income (Loss)USD | -10,572,508Source | -8,953,445Source | -7,973,228Source | -4,011,058Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -14,865,712Source | -9,028,181Source | -7,916,018Source | -8,151,654Source |
| Income Tax Expense (Benefit)USD | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| Net Income (Loss) Attributable to ParentUSD | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Earnings Per Share, BasicUSD per share | -8.66Source | -0.75Source | -0.91Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | -8.66Source | -0.75Source | -0.91Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,721,082Source | 12,125,029Source | 8,747,509Source | 4,498,964Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,721,082Source | 12,125,029Source | 8,747,509Source | — |
| Interest Expense (non-operating)USD | 44,372Source | 92,475Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 58,334Source | 58,333Source | 16,528Source | — |
| Current Income Tax Expense (Benefit)USD | 44,042Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 504,836Source | 605,637Source | 249,592Source | 10,182Source |
| Gross ProfitUSD | — | — | — | 4,336Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0.99Source | — |
| Interest ExpenseUSD | — | — | 37,125Source | 2,532,640Source |
| Investment Income, InterestUSD | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Nonoperating Income (Expense)USD | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Research and Development ExpenseUSD | 1,383,359Source | 1,461,227Source | 1,467,936Source | 1,142,777Source |
Offerings
Registration 333-296764
- Gross proceeds
- 120000.0
- Net proceeds
- 2961554.0
- Deal price
- 0.8
- Shares
- 150000
- Offering amount
- $120,000.
- Offering price
- $0.80
- Ticker
- BIAF
Registration 333-295465
Registration 333-290480
- Gross proceeds
- 4798284.03
- Net proceeds
- 4414421.31
- Deal price
- 2.5
- Shares
- 1919314
- Offering price
- $2.50
- Ticker
- BIAF
Registration 333-289944
Registration 333-286921
- Gross proceeds
- 3233400.58
- Net proceeds
- 2974728.54
- Deal price
- 0.32
- Shares
- 10104377
- Offering price
- $0.32
- Ticker
- BIAF
Registration 333-286497
Filing attachments
ex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans SAN ANTONIO, Texas - September 22, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the ear…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath® Lung Noninvasive Lung Cancer Diagnostic Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide SAN ANTONIO, Texas - September 17, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare …
Read attachment ↗ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements BIAF continues to be listed and traded on Nasdaq SAN ANTONIO, TX - September 9, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has received written notice from The Nasdaq Stock Market LLC stating that the Company…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SAN ANTONIO, Texas - September 3, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings during t…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-20
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 SAN ANTONIO, TX - August 20, 2026 - bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capi…
Read attachment ↗